SuperTrans Medical

SuperTrans Medical is a private anti-infectives biopharmaceutical company focused on developing novel antibiotics for multidrug-resistant bacterial infections. Its approach centers on chemically conjugating existing FDA-approved antibiotics with a guanidinium-rich molecular transporter technology licensed from Stanford University to improve bacterial penetration and broaden activity against hard-to-treat pathogens. The company has described this platform as Intelligent Repurposing and has advanced a lead antibiotic conjugate, STM-001, toward early clinical development. Public sources indicate the business operated across Israel and Australia, worked with Australian clinical-research vendors for a planned Phase 1 study, and received strategic investment support from Mediforum Pharm. However, the company appears to have entered liquidation in Australia in May 2024, so it should not be treated as an active operating biotech at present.